- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Propofol-based IV anesthesia improves survival during cancer surgery: Study
![Propofol-based IV anesthesia improves survival during cancer surgery: Study Propofol-based IV anesthesia improves survival during cancer surgery: Study](https://medicaldialogues.in/h-upload/uid/250x150_23690HRRlygn5l8RsdcM4ZtnjiHwwSHO45rxA6119456.jpg)
Taiwan: Cancer patients who receive propofol-based total intravenous anesthesia (TIVA) versus volatile anesthesia during surgery have better overall survival, finds a recent study in the journal Anesthesia & Analgesia. However, according to the authors, there is a need for further large-scaled, high-quality randomized control trials for confirming the findings.
Whether propofol helps in survival benefit versus volatile anesthetics during cancer surgery remains inconclusive. The primary aim of the systematic review and meta-analysis by Ming-Chang Kao, School of Medicine, Tzu Chi University, Hualien, Taiwan, and colleagues, was to to compare the effects of propofol-based TIVA with any volatile anesthesia on long-term oncological outcomes. Secondly, they aimed to compare propofol-based TIVA with specific volatile agents on long-term oncological outcomes.
For the study, the researchers searched the online databases from inception through March 3, 2020. It included randomized control trials and observational studies that compared the effects of propofol-based TIVA and volatile anesthesia on long-term oncological outcomes, which also reported hazard ratios (HR) as effect estimates.
Using the inverse variance method with a random-effects model, HR and 95% confidence intervals (CI) were calculated. Trial sequential analysis was incorporated to test if the results were subject to a type I or type II error.
A total of 19 retrospective observational studies were included.
Key findings of the study include:
- Patients who received propofol-based TIVA during cancer surgery were associated with significantly better overall survival than those who received volatile anesthesia (HR = 0.79).
- In contrast, no statistically significant difference was observed in recurrence-free survival between patients who received propofol-based TIVA and volatile anesthesia during cancer surgery (HR = 0.81).
- In the subgroup analysis by different volatile anesthetics, patients who received propofol-based TIVA were associated with better overall survival than those who received desflurane (HR = 0.54).
- In contrast, there was no statistically significant difference in overall survival between patients who received propofol-based TIVA and those who received sevoflurane (HR = 0.92).
- In the trial sequential analysis of overall survival, the cumulativez curve reached the required heterogeneity-adjusted information size and crossed the traditional significance boundary.
- In contrast, in the trial sequential analysis of recurrence-free survival, the cumulativez curve did not cross the traditional significance boundary. However, the required heterogeneity-adjusted information size has not yet been reached.
"Propofol-based TIVA is generally associated with better overall survival than volatile anesthesia during cancer surgery. Further large-scaled, high-quality randomized control trials are warranted to confirm our findings," concluded the authors.
The study titled, "Anesthesia and Long-term Oncological Outcomes: A Systematic Review and Meta-analysis," is published in the journal Anesthesia & Analgesia.
DOI: https://journals.lww.com/anesthesia-analgesia/fulltext/2021/03000/anesthesia_and_long_term_oncological_outcomes__a.6.aspx
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751